Nasonex Indications Will Help Deflect Competition From Allermist, Schering-Plough Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes mometasone’s broader label, which includes indications for allergy symptoms in children two years and older, will differentiate the product from GlaxoSmithKline’s Flonase follow-on.
You may also be interested in...
Schering-Plough To Bring Tablet-Based Allergy Vaccine To U.S. Market
Company signs deal with Dutch firm ALK-Abello to develop and commercialize the vaccine, marketed as Grazax in Europe.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.